P10.19.B An immunotoxin targeting CD317 for the treatment of glioblastoma

Abstract Background CD317 is an interferon-inducible cell surface receptor expressed in several solid cancer types. HM1.24-ETA’ a small immunotoxin with single-chain variable fragment (svFv) antibody fused to truncated version of Pseudomonas aeruginosa exotoxin A (ETA’) that explored as novel therapeutic approach CD317-expressing tumors. Material and Methods mRNA expression human gliomas its association survival was analyzed using the database Cancer Genome Atlas (TCGA). protein levels were assessed by immunohistochemistry. RT-PCR flow cytometry 13 glioma lines vitro. Efficacy acute cytotoxicity assays Finally, evaluated intracranial LN-229 xenograft nude mouse model after intravenous injection. Results Interrogation TCGA showed increased correlated grade malignancy among isocitrate dehydrogenase (IDH) wildtype IDH-mutant gliomas. Enhanced associated inferior glioblastoma astrocytoma, IDH-mutant, WHO 4. Immunohistochemistry confirmed overexpression compared lower astrocytomas. heterogeneously on induced CD317-positive cells susceptibility HM1.24-ETA’-induced death enhanced interferon-β. prolonged model. Conclusion These data define target for treatment immunoconjugates.